4D Molecular Therapeutics at Morgan Stanley conference: gene therapy push

On September 14, 2026, 4D Molecular Therapeutics (FDMT) presented its lead gene therapy, 4D-150, at the Morgan Stanley Global Healthcare Conference. The company highlighted strong clinical momentum and a large commercial opportunity for the treatment of wet age-related macular degeneration and other retinal diseases. Management acknowledged that FDMT still faces risks associated with late-stage drug development and future trial results.

4D-150 is designed to provide long-lasting benefit, measured in months, years, or even a lifetime for patients.

Phase III studies for 4D-150, known as 4FRONT, completed enrollment ahead of schedule with approximately 525 to 530 patients per trial and over 90% statistical power. Two-year PRISM data showed consistent safety profiles and treatment burden reduction in the 70% to 90% range. The company has $431 million in cash and cash equivalents, giving it a runway into the second half of 2028.

The partnership with Otsuka Pharmaceutical brought in over $110 million upfront for Asia-Pacific rights, with 4DMT retaining global rights to about 85% of the program's commercial value.

Founder and Chief Executive David Kirn emphasized that the company is pioneering next-generation gene therapy by using directed evolution to improve the vector, lower dose requirements, reduce manufacturing costs, improve safety, and support stronger efficacy than older gene therapy methods. Commercial Officer Chris stated that the goal is to extend durability much further, potentially by months, years, or even a lifetime for patients.

The Otsuka deal provided important non-dilutive capital, with the company's current balance sheet position being strong, as evidenced by a current ratio of 8.03 and liquid assets exceeding short-term obligations. The stock is currently trading below its Fair Value, placing it among the most undervalued companies. The Phase III data timeline is considered ahead by an InvestingPro tip, and the stock has shown volatility with a beta of 2.73.